Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13251MR)

This product GTTS-WQ13251MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13251MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12356MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ13109MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ2008MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ2067MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ3925MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ14013MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ8812MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ3116MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW